170 related articles for article (PubMed ID: 26861552)
1. Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma.
Chang MC; Chang YT; Chen JY; Jeng YM; Yang CY; Tien YW; Yang SH; Chen HL; Liang TY; Wang CF; Lee EY; Chang YC; Lee WH
Clin Chem; 2016 Mar; 62(3):505-13. PubMed ID: 26861552
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.
Hou JM; Krebs MG; Lancashire L; Sloane R; Backen A; Swain RK; Priest LJ; Greystoke A; Zhou C; Morris K; Ward T; Blackhall FH; Dive C
J Clin Oncol; 2012 Feb; 30(5):525-32. PubMed ID: 22253462
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact and potential predictive role of baseline circulating tumor cells in locally advanced head and neck squamous cell carcinoma.
Bueno de Oliveira T; Camila Braun A; Ribaldo Nicolau U; Ali Abdallah E; da Silva Alves V; Hugo Fonseca de Jesus V; Fernando Calsavara V; Paulo Kowaslki L; Domingos Chinen LT
Oral Oncol; 2021 Oct; 121():105480. PubMed ID: 34403888
[TBL] [Abstract][Full Text] [Related]
4. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse M; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
J Clin Oncol; 2008 Jul; 26(19):3213-21. PubMed ID: 18591556
[TBL] [Abstract][Full Text] [Related]
5. Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer.
Zheng X; Fan L; Zhou P; Ma H; Huang S; Yu D; Zhao L; Yang S; Liu J; Huang A; Cai C; Dai X; Zhang T
Transl Oncol; 2017 Jun; 10(3):431-441. PubMed ID: 28448959
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy.
Zhang D; Zhao L; Zhou P; Ma H; Huang F; Jin M; Dai X; Zheng X; Huang S; Zhang T
Cancer Cell Int; 2017; 17():6. PubMed ID: 28070168
[TBL] [Abstract][Full Text] [Related]
7. CTC phenotyping for a preoperative assessment of tumor metastasis and overall survival of pancreatic ductal adenocarcinoma patients.
Sun Y; Wu G; Cheng KS; Chen A; Neoh KH; Chen S; Tang Z; Lee PF; Dai M; Han RPS
EBioMedicine; 2019 Aug; 46():133-149. PubMed ID: 31375425
[TBL] [Abstract][Full Text] [Related]
8. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma.
Poruk KE; Blackford AL; Weiss MJ; Cameron JL; He J; Goggins M; Rasheed ZA; Wolfgang CL; Wood LD
Clin Cancer Res; 2017 Jun; 23(11):2681-2690. PubMed ID: 27789528
[No Abstract] [Full Text] [Related]
10. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of circulating tumor cells and analysis of clinicopathological factors in liver cancer.
Cui K; Ou Y; Ning D; Li H; Xi Y; Li S
J Cancer Res Ther; 2022 Apr; 18(2):452-460. PubMed ID: 35645114
[TBL] [Abstract][Full Text] [Related]
12. The rare circulating tumor microemboli as a biomarker contributes to predicting early colorectal cancer recurrences after medical treatment.
Hao YJ; Chang LW; Yang CY; Lo LC; Lin CP; Jian YW; Jiang JK; Tseng FG
Transl Res; 2024 Jan; 263():1-14. PubMed ID: 37558203
[TBL] [Abstract][Full Text] [Related]
13. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer.
Court CM; Ankeny JS; Sho S; Winograd P; Hou S; Song M; Wainberg ZA; Girgis MD; Graeber TG; Agopian VG; Tseng HR; Tomlinson JS
Ann Surg Oncol; 2018 Apr; 25(4):1000-1008. PubMed ID: 29442211
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy.
Giampieri R; Piva F; Occhipinti G; Bittoni A; Righetti A; Pagliaretta S; Murrone A; Bianchi F; Amantini C; Giulietti M; Ricci G; Principato G; Santoni G; Berardi R; Cascinu S
PLoS One; 2019; 14(5):e0215990. PubMed ID: 31048929
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of circulating tumor microemboli in patients with pancreatic ductal adenocarcinoma.
Wu G; Zhu R; Li Y; Zhao Y; Dai M
Oncol Lett; 2018 May; 15(5):7376-7382. PubMed ID: 29725451
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study.
Gemenetzis G; Groot VP; Yu J; Ding D; Teinor JA; Javed AA; Wood LD; Burkhart RA; Cameron JL; Makary MA; Weiss MJ; He J; Wolfgang CL
Ann Surg; 2018 Sep; 268(3):408-420. PubMed ID: 30080739
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma.
Vicente D; Lee AJ; Hall CS; Lucci A; Lee JE; Kim MP; Katz MHG; Hurd MW; Maitra A; Rhim Md AD; Tzeng CD
J Surg Res; 2019 Nov; 243():90-99. PubMed ID: 31170555
[TBL] [Abstract][Full Text] [Related]
18. Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma.
Chapin WJ; Till JE; Hwang WT; Eads JR; Karasic TB; O'Dwyer PJ; Schneider CJ; Teitelbaum UR; Romeo J; Black TA; Christensen TE; Redlinger Tabery C; Anderson A; Slade M; LaRiviere M; Yee SS; Reiss KA; O'Hara MH; Carpenter EL
JCO Precis Oncol; 2022 Jul; 6():e2200060. PubMed ID: 35939771
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of incidence, significance, and prognostic role of circulating tumor microemboli and transforming growth factor-β receptor I in head and neck cancer.
Fanelli MF; Oliveira TB; Braun AC; Corassa M; Abdallah EA; Nicolau UR; da Silva Alves V; Garcia D; Calsavara VF; Kowalski LP; Chinen LTD
Head Neck; 2017 Nov; 39(11):2283-2292. PubMed ID: 28815787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
